Paul Capital Healthcare Leads US$100+ Million Investment With UCB

NEW YORK, December 21 - Paul Capital Healthcare today announced that it has led an investment to
provide more than US$100 million to UCB S.A. in exchange for certain payments
relating to the sales of products marketed by third parties. The underlying
third party products (which are non-core to UCB) are leading brands in their
therapeutic fields.

"This transaction underscores Paul Capital Healthcare's continued ability
to help innovative companies access transformative growth capital," said Dr.
Ken Macleod in Paul Capital Healthcare's London office. "These are quality
products that have the support of strong marketing partners. We believe that
this transaction will provide benefit to both Paul Capital Healthcare and
UCB."

"As evidenced by this investment, Paul Capital Healthcare is committed to
working with companies to tailor transactions that meet their near-term
financial needs and long-term growth objectives," said Andrew Rubinstein in
Paul Capital Healthcare's New York office. "Our approach is an attractive
alternative to traditional equity and debt financing for a variety of
pharmaceutical, biotechnology and medical device companies in the United
States, Europe and Asia, including major global pharmaceutical companies such
as UCB."

About Paul Capital Healthcare and Paul Capital

Through its funds, Paul Capital Healthcare is one of the largest
dedicated healthcare investors globally, with more than US$1.6 billion in
equity capital commitments and debt facilities under management. Combined,
the Paul Capital Healthcare funds have invested more than US$1 billion in the
pharmaceutical, biotechnology, and medical device sectors. These investments
are focused on commercial stage companies and products, and consist of
investments in the form of royalties, revenue interests, debt and equity.
Additional information on Paul Capital Healthcare can be found at
www.paulcapitalhealthcare.com. Paul Capital Partners manages nearly US$7.3
billion in capital commitments for its three investment platforms, which
include Paul Capital Healthcare, Private Equity Secondary Funds and Top Tier
Fund-of-Funds. The firm has offices in New York, San Francisco, Paris,
London, Hong Kong, and Sao Paolo.

Susan Rood, +1-212-843-0210, srood at lazarpartners.com; or Stephanie Seiler, +1-206-713-0124, sseiler at lazarpartners.com, both of Paul Capital Healthcare; or Ken Macleod, Ph.D., Partner of Paul Capital Healthcare, +44-20-7514 0754, kmacleod at paulcap.com